| Trial ID # | NCT02853318 |
| Phase | II |
| Drug Class | Immunotherapy: Checkpoint Inhibitors/PD-1 |
| Drug Name | Pembrolizumab |
| Alternate Drug Names | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 |
| Drugs in Trial | Bevacizumab, Cyclophosphamide, Pembrolizumab |
| Eligible Participant | Platinum resistant or refractory ovarian cancer |
| Patients Enrolled | 30, mean of 3.8 prior therapies |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | CBR, ORR, DCR, PFS, evaluated per irRECIST |
| Efficacy | pembrolizumab 200 mg in combination with bevacizumab 15 mg/kg every 3 weeks and oral cyclophosphamide 50 mg every day ORR: 43.3% (3CR, 10PR, n=30) |
| Clinically Significant Adverse Events | Serious AE: |
| Conclusion | Pembrolizumab+bevacizumab+cyclophosphamide is well tolerated and demonstrates clinical benefit and durable treatment responses |
| Reference | Zsiros E et al. Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial. JAMA Oncol (2020) 7(1):78-85 |
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.